Summary
The response content is largely unsupported by the provided prescribing-information excerpts. The only label-supported elements in the provided text are: (1) UBRELVY is ubrogepant, a CGRP receptor antagonist (Description), (2) clinical efficacy in acute migraine with specified 2-hour endpoints (Clinical Studies), and (3) contraindications (Contras). Other claims (pricing/savings, approvals timeline, mechanism details beyond label wording, side effects, prior authorization/step therapy, and several clinical details) are not supported by the provided excerpts and may be inaccurate relative to the full label.
Category Scores
Accurate Statements
Ubrelvy (ubrogepant) is a calcitonin gene-related peptide (CGRP) receptor antagonist.
Description: “ubrogepant, a calcitonin gene-related peptide (CGRP) receptor antagonist.”
The efficacy of UBRELVY for the acute treatment of migraine was demonstrated in two randomized, double-blind, placebo-controlled trials (Study 1 and Study 2), including effects on pain freedom at 2 hours post-dose and most bothersome symptom (MBS) freedom at 2 hours post-dose.
Clinical Studies: efficacy demonstrated in two RDBPC trials; primary analyses include pain freedom at 2 hours and MBS freedom at 2 hours compared to placebo.
Ubrelvy (ubrogepant) is used for the acute treatment of migraine.
Clinical Studies: “efficacy of UBRELVY for the acute treatment of migraine…” (indication supported by provided excerpt context).
Unsupported Statements
The out-of-pocket cost for Ubrelvy can vary depending on insurance coverage, pharmacy, and the specific savings program used.
No label information provided about pricing or cost determinants.
Without insurance, the retail price for Ubrelvy can be substantial.
No label information provided about retail price or uninsured costs.
Manufacturer-sponsored savings programs may reduce out-of-pocket expenses for Ubrelvy.
No label information provided about manufacturer savings programs.
For eligible commercially insured patients, the Ubrelvy Savings Card may reduce the cost to as little as $0 for a monthly prescription.
No label information provided about savings card benefit amounts (e.g., $0).
Insurance coverage for Ubrelvy differs by plan.
No label information provided about insurance coverage requirements.
Many insurance providers may require prior authorization before covering Ubrelvy.
No label information provided about prior authorization.
Some insurance plans may require step therapy for Ubrelvy, meaning patients might need to try other migraine medications first.
No label information provided about step therapy.
Copay assistance programs are available for Ubrelvy.
No label information provided about copay assistance.
The Ubrelvy Savings Card is designed to help eligible patients with commercial insurance reduce out-of-pocket costs.
No label information provided about savings card design/eligibility.
The Ubrelvy Savings Card can lower copayments to a specified amount per prescription.
No label information provided about copay limits per prescription.
The Ubrelvy Savings Card has certain limitations and maximum savings per year.
No label information provided about maximum savings per year/limitations.
Patient assistance programs may offer Ubrelvy at no cost for patients who meet specific financial and insurance criteria.
No label information provided about patient assistance programs or no-cost eligibility.
Patient assistance programs typically have strict eligibility requirements.
No label information provided about patient assistance program eligibility criteria.
Ubrelvy works by blocking the action of CGRP.
The provided label excerpt specifies CGRP receptor antagonist but does not state “blocking the action of CGRP.”
By inhibiting CGRP, Ubrelvy helps reduce inflammation and vasodilation that contribute to migraine pain.
No label excerpt provided stating that mechanism of action includes reducing inflammation/vasodilation.
Common side effects of Ubrelvy include nausea, fatigue, and dry mouth.
No adverse reactions section content is provided in the excerpts; therefore side-effect claims are unsupported.
Ubrelvy was approved by the U.S. Food and Drug Administration (FDA) in December 2019.
No label excerpt provided stating FDA approval month/year.
Contradictions
Low
AI Statement
Ubrelvy (ubrogepant) works by blocking the action of CGRP.
Label Reference
Description (provided): “CGRP receptor antagonist.”
Important Omissions
Clear linkage of contraindications and warnings to the statements made (the response includes none of the label contraindications; however the response does not attempt to describe contraindications).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported statements about common side effects and cost/assistance program details could mislead users, but no direct contraindication-ignoring dosing/safety instruction was provided in the response. However, mechanism and side-effect assertions are not supported by the provided label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Mostly Not Aligned
Primary Issue
Most statements (pricing, savings cards, prior authorization/step therapy, patient assistance, side effects, FDA approval timing, and additional mechanism details) are not supported by the provided prescribing-information excerpts.
Suggested Improvement
Limit claims to what is present in the provided label text (e.g., CGRP receptor antagonist identity; clinical efficacy endpoints from Section 14; contraindications from Section 4 if discussed). Remove or qualify unsupported claims, especially cost/savings and adverse reaction statements, unless supported by the full label.